Resumen
Current limitation in cancer genomic studies is a lack of the integration of various omics data generated through next generation sequencing technologies, as well as a lack of the sounding and comprehensive epigenomic and genomic information about a particular cancer cell type. In this review, we will discuss main aspects of current genomics research with its application in cancer topics. We will first overview the next-generation sequencing technologies, then outline the major computational approaches, particularly focusing on ChIP-based omics data, and list several remaining open questions facing computational biologists, further present regulatory network analysis inferred from the ChIP-based omics data; finally implicate the clinical outcomes from the network and pathway analysis.
| Idioma original | English (US) |
|---|---|
| Páginas (desde-hasta) | 277-283 |
| Número de páginas | 7 |
| Publicación | Cancer Letters |
| Volumen | 340 |
| N.º | 2 |
| DOI | |
| Estado | Published - nov 1 2013 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Huella
Profundice en los temas de investigación de 'Cancer omics: From regulatory networks to clinical outcomes'. En conjunto forman una huella única.Citar esto
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS